Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

AAMIR Z JAMAL

Allopathic & Osteopathic Physicians Internal Medicine Nephrology

NPI
1558377523
CMS profile
251829
Location
SAN DIMAS, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2025 · Entire year

$1,061.81

51 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2025 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $997.27 49
Education $64.54 2

By paying entity

PY2025 · entire year · sorted by reported total

Page 2 of 2; records 51–51 of 51 matching records. This page contains 1 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

AAMIR Z JAMAL

NPI 1558377523 · CMS profile ID 251829

Allopathic & Osteopathic Physicians / Internal Medicine / Nephrology

SAN DIMAS, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 2; records 51–51 of 51 matching records. This page contains 1 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1558377523?year=2025&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
AAMIR Z JAMAL, NPI 1558377523, CMS profile ID 251829. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–51 of 51 matching records. This page contains 1 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1558377523?year=2025&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
APA 7
IndustryPayments. (2026). AAMIR Z JAMAL, NPI 1558377523, CMS profile ID 251829. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–51 of 51 matching records. This page contains 1 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1558377523?year=2025&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
Bluebook
AAMIR Z JAMAL, NPI 1558377523, CMS profile ID 251829, IndustryPayments, General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 2; records 51–51 of 51 matching records. This page contains 1 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e. https://industrypayments.org/provider/npi-1558377523?year=2025&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2025 · Physicians and non-physician practitioners · CMS publication 2026-06-30

51 matching records · $1,061.81 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 51 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–51 of 51.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
AstraZeneca Pharmaceuticals LP $32.6901/16/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1206588213 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $430.51 18
PY2020 $291.42 15
PY2021 $5,030.27 21
PY2022 $560.25 19
PY2023 $530.13 23
PY2024 $1,072.99 41
PY2025 $1,061.81 51

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $24.90 1
PY2025 Principal investigator $1,471,601.02 167
PY2024 Recipient $29,425.21 2
PY2024 Principal investigator $1,181,501.87 263
PY2023 Recipient $217.78 3
PY2023 Principal investigator $322,549.59 383
PY2022 Recipient $31,851.60 3
PY2022 Principal investigator $307,450.33 500
PY2021 Principal investigator $679,075.50 672
PY2020 Recipient $4,193.87 2
PY2020 Principal investigator $813,384.42 208
PY2019 Recipient $1,476.97 11
PY2019 Principal investigator $699,383.42 730

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

168 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 CSL Behring $38,437.00 12/29/2025 Non-covered Recipient Entity
North America Research Institute
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252667717
Principal investigator 1 CSL Behring $1,074.22 12/18/2025 Non-covered Recipient Entity
North America Research Institute
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252667915
Principal investigator 1 CSL Behring $540.54 12/18/2025 Non-covered Recipient Entity
North America Research Institute
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252667923
Principal investigator 1 Boehringer Ingelheim International GmbH $11.66 12/17/2025 Non-covered Recipient Entity
California Kidney Specialists
A simultaneous vs. staggered initiation study of BI 690517 and empagliflozin for SGLT2i treatment-naive participants with CKD No dispute reported 06/30/2026 1220718423
Principal investigator 1 Boehringer Ingelheim International GmbH $19.98 12/17/2025 Non-covered Recipient Entity
California Kidney Specialists
A simultaneous vs. staggered initiation study of BI 690517 and empagliflozin for SGLT2i treatment-naive participants with CKD No dispute reported 06/30/2026 1220718425
Principal investigator 1 Boehringer Ingelheim International GmbH $73.00 12/15/2025 Non-covered Recipient Entity
California Kidney Specialists
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220718493
Principal investigator 1 Boehringer Ingelheim International GmbH $73.00 12/15/2025 Non-covered Recipient Entity
California Kidney Specialists
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220718495
Principal investigator 1 Boehringer Ingelheim International GmbH $325.00 12/15/2025 Non-covered Recipient Entity
California Kidney Specialists
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220718497
Principal investigator 1 Boehringer Ingelheim International GmbH $325.00 12/15/2025 Non-covered Recipient Entity
California Kidney Specialists
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220718499
Principal investigator 1 Boehringer Ingelheim International GmbH $1,952.00 12/15/2025 Non-covered Recipient Entity
California Kidney Specialists
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220718501
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 12/01/2025 Non-covered Recipient Entity
California Kidney Specialists
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220718489
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 12/01/2025 Non-covered Recipient Entity
California Kidney Specialists
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220718491
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $6,676.96 11/26/2025 Non-covered Recipient Entity
California Kidney Specialists
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220997094
Principal investigator 1 CSL Behring $86.48 11/20/2025 Non-covered Recipient Entity
North America Research Institute
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252667921
Principal investigator 1 Boehringer Ingelheim International GmbH $3,234.00 11/19/2025 Non-covered Recipient Entity
California Kidney Specialists
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220718479
Principal investigator 1 Boehringer Ingelheim International GmbH $338.00 11/19/2025 Non-covered Recipient Entity
California Kidney Specialists
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220718481
Principal investigator 1 Boehringer Ingelheim International GmbH $3,235.00 11/19/2025 Non-covered Recipient Entity
California Kidney Specialists
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220718483
Principal investigator 1 Boehringer Ingelheim International GmbH $1,293.00 11/19/2025 Non-covered Recipient Entity
California Kidney Specialists
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220718485
Principal investigator 1 Boehringer Ingelheim International GmbH $2,844.00 11/19/2025 Non-covered Recipient Entity
California Kidney Specialists
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220718487
Principal investigator 1 CSL Behring $19,174.00 11/17/2025 Non-covered Recipient Entity
North America Research Institute
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252667709
Principal investigator 1 CSL Behring $97.31 11/17/2025 Non-covered Recipient Entity
North America Research Institute
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252667919
Principal investigator 1 CSL Behring $291.88 11/13/2025 Non-covered Recipient Entity
North America Research Institute
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252667897
Principal investigator 1 CSL Behring $1,081.08 11/12/2025 Non-covered Recipient Entity
North America Research Institute
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252667895
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $5,007.72 11/11/2025 Non-covered Recipient Entity
California Kidney Specialists
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220997092
Principal investigator 1 Eli Lilly and Company $77.33 11/10/2025 Non-covered Recipient Entity
NORTH AMERICA RESEARCH INSTITUTE
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, EVENT-DRIVEN STUDY TO INVESTIGATE THE EFFECT OF RETATRUTIDE ON THE INCIDENCE OF MAJOR ADVERSE CARDIOVASCULAR EVENTS AND THE DECLINE IN KIDNEY FUNCTION IN PARTICIPANTS WITH BODY MASS INDEX GREATER THAN 27 KG M2 AND ATHEROSCLEROTIC CARDIOVASCULAR DISEASE AND OR CHRONIC KIDNEY DISEASE No dispute reported 06/30/2026 1187889242
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 11/01/2025 Non-covered Recipient Entity
California Kidney Specialists
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220718475
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 11/01/2025 Non-covered Recipient Entity
California Kidney Specialists
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220718477
Principal investigator 1 AstraZeneca Pharmaceuticals LP $8,930.00 10/31/2025 Non-covered Recipient Entity
NORTH AMERICA RESEARCH INSTITUTE
A Phase III, Randomised, Double-blind, Placebo-controlled, Parallel-group Study to Assess the Effect of AZD0780 on Major Adverse Cardiovascular Events in Patients with Established Atherosclerotic Cardiovascular Disease (ASCVD) or at High Risk for a First ASCVD Event No dispute reported 06/30/2026 1185538142
Principal investigator 1 Novartis Pharmaceuticals Corporation $22,443.79 10/30/2025 Non-covered Recipient Entity
CALIFORNIA KIDNEY SPECIALISTS
A Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel Group, Phase III Study to Evaluate the Efficacy and Safety of LNP023 in Primary IgA Nephropathy Patients No dispute reported 06/30/2026 1190303387
Principal investigator 1 CSL Behring $54,590.30 10/29/2025 Non-covered Recipient Entity
North America Research Institute
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252667701
Principal investigator 1 CSL Behring $702.65 10/28/2025 Non-covered Recipient Entity
North America Research Institute
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252667893
Principal investigator 1 Boehringer Ingelheim International GmbH $11.66 10/27/2025 Non-covered Recipient Entity
California Kidney Specialists
A simultaneous vs. staggered initiation study of BI 690517 and empagliflozin for SGLT2i treatment-naive participants with CKD No dispute reported 06/30/2026 1220718419
Principal investigator 1 Boehringer Ingelheim International GmbH $19.98 10/27/2025 Non-covered Recipient Entity
California Kidney Specialists
A simultaneous vs. staggered initiation study of BI 690517 and empagliflozin for SGLT2i treatment-naive participants with CKD No dispute reported 06/30/2026 1220718421
Principal investigator 1 Boehringer Ingelheim International GmbH $1,293.00 10/20/2025 Non-covered Recipient Entity
California Kidney Specialists
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220718473
Principal investigator 1 CSL Behring $835.38 10/07/2025 Non-covered Recipient Entity
North America Research Institute
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252667885
Principal investigator 1 Boehringer Ingelheim International GmbH $3,235.00 10/02/2025 Non-covered Recipient Entity
California Kidney Specialists
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220718461
Principal investigator 1 Boehringer Ingelheim International GmbH $325.00 10/02/2025 Non-covered Recipient Entity
California Kidney Specialists
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220718463
Principal investigator 1 Boehringer Ingelheim International GmbH $2,726.00 10/02/2025 Non-covered Recipient Entity
California Kidney Specialists
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220718465
Principal investigator 1 Boehringer Ingelheim International GmbH $2,844.00 10/02/2025 Non-covered Recipient Entity
California Kidney Specialists
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220718467
Principal investigator 1 Boehringer Ingelheim International GmbH $1,952.00 10/02/2025 Non-covered Recipient Entity
California Kidney Specialists
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220718469
Principal investigator 1 Boehringer Ingelheim International GmbH $2,925.00 10/02/2025 Non-covered Recipient Entity
California Kidney Specialists
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220718471
Principal investigator 1 CSL Behring $352.45 10/02/2025 Non-covered Recipient Entity
North America Research Institute
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252667879
Principal investigator 1 Hoffmann-La Roche Limited $4,306.00 10/02/2025 Non-covered Recipient Entity
NORTH AMERICA RESEARCH INSTITUTE
Double blind study to determine efficacy of ASO Factor B in IgAN No dispute reported 06/30/2026 1211629868
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 10/01/2025 Non-covered Recipient Entity
California Kidney Specialists
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220718457
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 10/01/2025 Non-covered Recipient Entity
California Kidney Specialists
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220718459
Principal investigator 1 Boehringer Ingelheim International GmbH $99.90 09/24/2025 Non-covered Recipient Entity
California Kidney Specialists
EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% No dispute reported 06/30/2026 1220718435
Principal investigator 1 Boehringer Ingelheim International GmbH $179.82 09/24/2025 Non-covered Recipient Entity
California Kidney Specialists
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220718449
Principal investigator 1 Boehringer Ingelheim International GmbH $255.50 09/24/2025 Non-covered Recipient Entity
California Kidney Specialists
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220718451
Principal investigator 1 Boehringer Ingelheim International GmbH $4.35 09/24/2025 Non-covered Recipient Entity
California Kidney Specialists
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220718453
Principal investigator 1 Boehringer Ingelheim International GmbH $5.64 09/24/2025 Non-covered Recipient Entity
California Kidney Specialists
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220718455
Principal investigator 1 Novo Nordisk AS $7,500.00 09/19/2025 Non-covered Recipient Entity
NORTH AMERICA RESEARCH INSTITUTE
NN9535-4662 No dispute reported 06/30/2026 1213713874
Principal investigator 1 Novo Nordisk AS $500.00 09/19/2025 Non-covered Recipient Entity
NORTH AMERICA RESEARCH INSTITUTE
NN9535-4662 No dispute reported 06/30/2026 1213718277
Principal investigator 1 Novo Nordisk AS $380.00 09/19/2025 Non-covered Recipient Entity
NORTH AMERICA RESEARCH INSTITUTE
NN9535-4662 No dispute reported 06/30/2026 1213734148
Principal investigator 1 Novo Nordisk AS $2,100.00 09/19/2025 Non-covered Recipient Entity
NORTH AMERICA RESEARCH INSTITUTE
NN9535-4662 No dispute reported 06/30/2026 1213754646
Principal investigator 1 Novo Nordisk AS $6,083.00 09/19/2025 Non-covered Recipient Entity
NORTH AMERICA RESEARCH INSTITUTE
NN9535-4662 No dispute reported 06/30/2026 1213814483
Principal investigator 1 Novo Nordisk AS $846.93 09/19/2025 Non-covered Recipient Entity
NORTH AMERICA RESEARCH INSTITUTE
NN9535-4662 No dispute reported 06/30/2026 1213818116
Principal investigator 1 Novo Nordisk AS $1,295.00 09/19/2025 Non-covered Recipient Entity
NORTH AMERICA RESEARCH INSTITUTE
NN9535-4662 No dispute reported 06/30/2026 1213833461
Principal investigator 1 Novo Nordisk AS $62.50 09/19/2025 Non-covered Recipient Entity
NORTH AMERICA RESEARCH INSTITUTE
NN9535-4662 No dispute reported 06/30/2026 1213841213
Principal investigator 1 Novo Nordisk AS $475.00 09/19/2025 Non-covered Recipient Entity
NORTH AMERICA RESEARCH INSTITUTE
NN9535-4662 No dispute reported 06/30/2026 1213847656
Principal investigator 1 CSL Behring $32,983.60 09/17/2025 Non-covered Recipient Entity
North America Research Institute
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252667691
Principal investigator 1 CSL Behring $581.61 09/08/2025 Non-covered Recipient Entity
North America Research Institute
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252667871
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 09/01/2025 Non-covered Recipient Entity
California Kidney Specialists
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220718437
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 09/01/2025 Non-covered Recipient Entity
California Kidney Specialists
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220718439
Principal investigator 1 Alexion Pharmaceuticals, Inc. $7,295.68 08/27/2025 Non-covered Recipient Entity
NORTH AMERICA RESEARCH INSTITUTE
A Phase 2, Double Blind, Randomized, Placebo Controlled Study of Ravulizumab in Adult Participants with Proliferative Lupus Nephritis (LN) or Immunoglobulin A Nephropathy (IgAN) No dispute reported 06/30/2026 1185538138
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $1,665.37 08/22/2025 Non-covered Recipient Entity
North America Research Institute
A randomized, double-blind, placebo-controlled, parallel-group, multicenter Phase 3 study to investigate the efficacy and safety of FInerenone, in addition to standard of care, on the progression of kidney disease in patients with Non-Diabetic Chronic K No dispute reported 06/30/2026 1225413454
Principal investigator 1 Boehringer Ingelheim International GmbH $2,665.00 08/20/2025 Non-covered Recipient Entity
California Kidney Specialists
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220718445
Principal investigator 1 CSL Behring $41,388.30 08/20/2025 Non-covered Recipient Entity
North America Research Institute
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252667683
Principal investigator 1 CSL Behring $983.29 08/18/2025 Non-covered Recipient Entity
North America Research Institute
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252667861
Principal investigator 1 CSL Behring $16.71 08/06/2025 Non-covered Recipient Entity
North America Research Institute
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252667873
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $3,338.48 08/05/2025 Non-covered Recipient Entity
California Kidney Specialists
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220997090
Principal investigator 1 Janssen Research & Development, LLC $18,422.00 08/05/2025 Non-covered Recipient Entity
N Amercn Rsrch Inst
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 1175167334
Principal investigator 1 Janssen Research & Development, LLC $9,430.00 08/05/2025 Non-covered Recipient Entity
N Amercn Rsrch Inst
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 1175167358
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 08/01/2025 Non-covered Recipient Entity
California Kidney Specialists
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220718567
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 08/01/2025 Non-covered Recipient Entity
California Kidney Specialists
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220718569
Principal investigator 1 Boehringer Ingelheim International GmbH $59.94 07/28/2025 Non-covered Recipient Entity
California Kidney Specialists
EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% No dispute reported 06/30/2026 1220718433
Principal investigator 1 Boehringer Ingelheim International GmbH $59.94 07/28/2025 Non-covered Recipient Entity
California Kidney Specialists
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220718447
Principal investigator 1 Janssen Research & Development, LLC $279.00 07/28/2025 Non-covered Recipient Entity
N Amercn Rsrch Inst
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 1175167305
Principal investigator 1 CSL Behring $734.68 07/23/2025 Non-covered Recipient Entity
North America Research Institute
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252667855
Principal investigator 1 Aurinia Pharma U.S., Inc. $1,848.00 07/16/2025 Non-covered Recipient Entity
North America Research Institute, Inc.
LUPKYNIS Registry Study No dispute reported 06/30/2026 1243931270
Principal investigator 1 Aurinia Pharma U.S., Inc. $4,200.00 07/16/2025 Non-covered Recipient Entity
North America Research Institute, Inc.
LUPKYNIS Registry Study No dispute reported 06/30/2026 1243931272
Principal investigator 1 CSL Behring $30,531.90 07/16/2025 Non-covered Recipient Entity
North America Research Institute
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252667675
Principal investigator 1 Hoffmann-La Roche Limited $6,436.00 07/08/2025 Non-covered Recipient Entity
NORTH AMERICA RESEARCH INSTITUTE
Double blind study to determine efficacy of ASO Factor B in IgAN No dispute reported 06/30/2026 1211629863
Principal investigator 1 Boehringer Ingelheim International GmbH $46.88 07/01/2025 Non-covered Recipient Entity
California Kidney Specialists
A simultaneous vs. staggered initiation study of BI 690517 and empagliflozin for SGLT2i treatment-naive participants with CKD No dispute reported 06/30/2026 1220718417
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 07/01/2025 Non-covered Recipient Entity
California Kidney Specialists
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220718441
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 07/01/2025 Non-covered Recipient Entity
California Kidney Specialists
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220718443
Principal investigator 1 CSL Behring $10,455.00 06/30/2025 Non-covered Recipient Entity
North America Research Institute
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252667667
Principal investigator 1 Novo Nordisk AS $8,840.93 06/25/2025 Non-covered Recipient Entity
NORTH AMERICA RESEARCH INSTITUTE
NN9535-4662 No dispute reported 06/30/2026 1213721780
Principal investigator 1 Novo Nordisk AS $2,000.00 06/25/2025 Non-covered Recipient Entity
NORTH AMERICA RESEARCH INSTITUTE
NN9535-4662 No dispute reported 06/30/2026 1213816662
Principal investigator 1 Boehringer Ingelheim International GmbH $58.30 06/24/2025 Non-covered Recipient Entity
California Kidney Specialists
A simultaneous vs. staggered initiation study of BI 690517 and empagliflozin for SGLT2i treatment-naive participants with CKD No dispute reported 06/30/2026 1220718411
Principal investigator 1 Boehringer Ingelheim International GmbH $159.84 06/24/2025 Non-covered Recipient Entity
California Kidney Specialists
A simultaneous vs. staggered initiation study of BI 690517 and empagliflozin for SGLT2i treatment-naive participants with CKD No dispute reported 06/30/2026 1220718413
Principal investigator 1 Boehringer Ingelheim International GmbH $36.50 06/24/2025 Non-covered Recipient Entity
California Kidney Specialists
A simultaneous vs. staggered initiation study of BI 690517 and empagliflozin for SGLT2i treatment-naive participants with CKD No dispute reported 06/30/2026 1220718415
Principal investigator 1 Boehringer Ingelheim International GmbH $139.92 06/24/2025 Non-covered Recipient Entity
California Kidney Specialists
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220718559
Principal investigator 1 Boehringer Ingelheim International GmbH $328.50 06/24/2025 Non-covered Recipient Entity
California Kidney Specialists
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220718561
Principal investigator 1 Boehringer Ingelheim International GmbH $3.48 06/24/2025 Non-covered Recipient Entity
California Kidney Specialists
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220718563
Principal investigator 1 Boehringer Ingelheim International GmbH $2.82 06/24/2025 Non-covered Recipient Entity
California Kidney Specialists
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220718565
Principal investigator 1 Boehringer Ingelheim International GmbH $246.00 06/20/2025 Non-covered Recipient Entity
California Kidney Specialists
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220718555
Principal investigator 1 CSL Behring $484.30 06/20/2025 Non-covered Recipient Entity
North America Research Institute
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252667845
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,650.00 06/13/2025 Non-covered Recipient Entity
NORTH AMERICAN RESEARCH INST
Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) No dispute reported 06/30/2026 1215511653
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,538.00 06/13/2025 Non-covered Recipient Entity
NORTH AMERICAN RESEARCH INST
Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) No dispute reported 06/30/2026 1215511656
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,926.00 06/13/2025 Non-covered Recipient Entity
NORTH AMERICAN RESEARCH INST
Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) No dispute reported 06/30/2026 1215511660
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,080.00 06/13/2025 Non-covered Recipient Entity
NORTH AMERICAN RESEARCH INST
Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) No dispute reported 06/30/2026 1215511664
Principal investigator 1 Alnylam Pharmaceuticals Inc. $2,200.00 06/13/2025 Non-covered Recipient Entity
NORTH AMERICAN RESEARCH INST
Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) No dispute reported 06/30/2026 1215511669
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $5,007.72 06/13/2025 Non-covered Recipient Entity
California Kidney Specialists
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220997088
Principal investigator 1 CSL Behring $432.43 06/10/2025 Non-covered Recipient Entity
North America Research Institute
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252667787
Principal investigator 1 Boehringer Ingelheim International GmbH $1,188.00 06/06/2025 Non-covered Recipient Entity
California Kidney Specialists
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220718549
Principal investigator 1 Boehringer Ingelheim International GmbH $1,415.00 06/06/2025 Non-covered Recipient Entity
California Kidney Specialists
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220718551
Principal investigator 1 Boehringer Ingelheim International GmbH $366.00 06/06/2025 Non-covered Recipient Entity
California Kidney Specialists
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220718553
Principal investigator 1 CSL Behring $1,178.39 06/06/2025 Non-covered Recipient Entity
North America Research Institute
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252667791
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 06/01/2025 Non-covered Recipient Entity
California Kidney Specialists
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220718545
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 06/01/2025 Non-covered Recipient Entity
California Kidney Specialists
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220718547
Principal investigator 1 Boehringer Ingelheim International GmbH $34.98 05/27/2025 Non-covered Recipient Entity
California Kidney Specialists
EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% No dispute reported 06/30/2026 1220718427
Principal investigator 1 Boehringer Ingelheim International GmbH $359.64 05/27/2025 Non-covered Recipient Entity
California Kidney Specialists
EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% No dispute reported 06/30/2026 1220718429
Principal investigator 1 Boehringer Ingelheim International GmbH $36.50 05/27/2025 Non-covered Recipient Entity
California Kidney Specialists
EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% No dispute reported 06/30/2026 1220718431
Principal investigator 1 Hoffmann-La Roche Limited $2,130.00 05/27/2025 Non-covered Recipient Entity
NORTH AMERICA RESEARCH INSTITUTE
Double blind study to determine efficacy of ASO Factor B in IgAN No dispute reported 06/30/2026 1211629859
Principal investigator 1 Janssen Research & Development, LLC $3,489.00 05/20/2025 Non-covered Recipient Entity
N Amercn Rsrch Inst
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 1175167350
Principal investigator 1 CSL Behring $20,733.00 05/14/2025 Non-covered Recipient Entity
North America Research Institute
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252667659
Principal investigator 1 CSL Behring $1,459.42 05/12/2025 Non-covered Recipient Entity
North America Research Institute
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252667777
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $6,676.96 05/09/2025 Non-covered Recipient Entity
California Kidney Specialists
Ph III HFrEF study No dispute reported 06/30/2026 1220997084
Principal investigator 1 Aurinia Pharma U.S., Inc. $700.00 05/07/2025 Non-covered Recipient Entity
North America Research Institute, Inc.
LUPKYNIS Registry Study No dispute reported 06/30/2026 1243930767
Principal investigator 1 CSL Behring $1,708.53 05/06/2025 Non-covered Recipient Entity
North America Research Institute
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252667771
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $1,494.79 05/05/2025 Non-covered Recipient Entity
North America Research Institute
A randomized, double-blind, placebo-controlled, parallel-group, multicenter Phase 3 study to investigate the efficacy and safety of FInerenone, in addition to standard of care, on the progression of kidney disease in patients with Non-Diabetic Chronic K No dispute reported 06/30/2026 1225412708
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 05/01/2025 Non-covered Recipient Entity
California Kidney Specialists
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220718541
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 05/01/2025 Non-covered Recipient Entity
California Kidney Specialists
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220718543
Principal investigator 1 Boehringer Ingelheim International GmbH $2,408.00 04/25/2025 Non-covered Recipient Entity
California Kidney Specialists
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220718537
Principal investigator 1 Boehringer Ingelheim International GmbH $11.20 04/25/2025 Non-covered Recipient Entity
California Kidney Specialists
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220718539
Principal investigator 1 Boehringer Ingelheim International GmbH $1.55 04/23/2025 Non-covered Recipient Entity
California Kidney Specialists
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220718557
Principal investigator 1 CSL Behring $291.92 04/17/2025 Non-covered Recipient Entity
North America Research Institute
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252667765
Principal investigator 1 Janssen Research & Development, LLC $884.00 04/17/2025 Non-covered Recipient Entity
N Amercn Rsrch Inst
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 1175167342
Principal investigator 1 CSL Behring $11,148.00 04/16/2025 Non-covered Recipient Entity
North America Research Institute
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252667651
Principal investigator 1 CSL Behring $423.76 04/16/2025 Non-covered Recipient Entity
North America Research Institute
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252667763
Principal investigator 1 CSL Behring $627.04 04/11/2025 Non-covered Recipient Entity
North America Research Institute
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252667761
Principal investigator 1 CSL Behring $16.71 04/09/2025 Non-covered Recipient Entity
North America Research Institute
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252667789
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 04/01/2025 Non-covered Recipient Entity
California Kidney Specialists
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220718533
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 04/01/2025 Non-covered Recipient Entity
California Kidney Specialists
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220718535
Principal investigator 1 CSL Behring $302.69 03/31/2025 Non-covered Recipient Entity
North America Research Institute
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252667751
Principal investigator 1 AstraZeneca Pharmaceuticals LP $4,200.00 03/26/2025 Non-covered Recipient Entity
NORTH AMERICA RESEARCH INSTITUTE
A Randomized DoubleBlind Parallel Group Multi Center Phase III Study to Assess the Efficacy of Budesonide Glycopyrronium and Formoterol Fumarate MeterednDose Inhaler Relative to Glycopyrronium and Formoterol Fumarate MDI on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease THARROS No dispute reported 06/30/2026 1185538140
Principal investigator 1 Boehringer Ingelheim International GmbH $179.82 03/25/2025 Non-covered Recipient Entity
California Kidney Specialists
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220718523
Principal investigator 1 Boehringer Ingelheim International GmbH $182.50 03/25/2025 Non-covered Recipient Entity
California Kidney Specialists
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220718525
Principal investigator 1 Boehringer Ingelheim International GmbH $3.76 03/25/2025 Non-covered Recipient Entity
California Kidney Specialists
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220718527
Principal investigator 1 Janssen Research & Development, LLC $558.00 03/25/2025 Non-covered Recipient Entity
N Amercn Rsrch Inst
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 1175167327
Principal investigator 1 CSL Behring $7,086.30 03/19/2025 Non-covered Recipient Entity
North America Research Institute
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252667643
Principal investigator 1 CSL Behring $786.05 03/10/2025 Non-covered Recipient Entity
North America Research Institute
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252667743
Principal investigator 1 Otsuka Pharmaceutical Development & Commercialization, Inc. $2,664.90 03/06/2025 Non-covered Recipient Entity
NORTH AMERICA RESEARCH INSTITUTE
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF SIBEPRENLIMAB ADMINISTERED SUBCUTANEOUSLY IN SUBJECTS WITH IMMUNOGLOBULIN A NEPHROPATHY No dispute reported 06/30/2026 1225335609
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 03/01/2025 Non-covered Recipient Entity
California Kidney Specialists
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220718513
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 03/01/2025 Non-covered Recipient Entity
California Kidney Specialists
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220718515
Principal investigator 1 Alnylam Pharmaceuticals Inc. $3,836.70 02/21/2025 Non-covered Recipient Entity
NORTH AMERICAN RESEARCH INST
Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) No dispute reported 06/30/2026 1215511590
Principal investigator 1 CSL Behring $483.71 02/21/2025 Non-covered Recipient Entity
North America Research Institute
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252667727
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $3,338.48 02/19/2025 Non-covered Recipient Entity
California Kidney Specialists
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220997086
Principal investigator 1 CSL Behring $8,195.00 02/19/2025 Non-covered Recipient Entity
North America Research Institute
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252667637
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 02/01/2025 Non-covered Recipient Entity
California Kidney Specialists
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220718509
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 02/01/2025 Non-covered Recipient Entity
California Kidney Specialists
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220718511
Principal investigator 1 Boehringer Ingelheim International GmbH $210.00 01/31/2025 Non-covered Recipient Entity
California Kidney Specialists
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220718517
Principal investigator 1 Eli Lilly and Company $59,158.00 01/28/2025 Non-covered Recipient Entity
NORTH AMERICA RESEARCH INSTITUTE
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, EVENT-DRIVEN STUDY TO INVESTIGATE THE EFFECT OF RETATRUTIDE ON THE INCIDENCE OF MAJOR ADVERSE CARDIOVASCULAR EVENTS AND THE DECLINE IN KIDNEY FUNCTION IN PARTICIPANTS WITH BODY MASS INDEX GREATER THAN 27 KG M2 AND ATHEROSCLEROTIC CARDIOVASCULAR DISEASE AND OR CHRONIC KIDNEY DISEASE No dispute reported 06/30/2026 1187889238
Principal investigator 1 Boehringer Ingelheim International GmbH $1.74 01/27/2025 Non-covered Recipient Entity
California Kidney Specialists
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220718519
Principal investigator 1 Boehringer Ingelheim International GmbH $3.76 01/27/2025 Non-covered Recipient Entity
California Kidney Specialists
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220718521
Principal investigator 1 Boehringer Ingelheim International GmbH $99.90 01/27/2025 Non-covered Recipient Entity
California Kidney Specialists
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220718529
Principal investigator 1 Boehringer Ingelheim International GmbH $146.00 01/27/2025 Non-covered Recipient Entity
California Kidney Specialists
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220718531
Principal investigator 1 AstraZeneca Pharmaceuticals LP $68,752.14 01/24/2025 Non-covered Recipient Entity
NORTH AMERICA RESEARCH INSTITUTE
A Phase III, Randomised, Multicentre, Double-blind Study to Evaluate the Efficacy, Safety and Tolerability of Zibotentan/Dapagliflozin FDC Compared to Dapagliflozin Alone in Participants with Chronic Kidney Disease and High Proteinuria No dispute reported 06/30/2026 1185538136
Principal investigator 1 Boehringer Ingelheim International GmbH $246.00 01/22/2025 Non-covered Recipient Entity
California Kidney Specialists
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220718503
Recipient Eli Lilly and Company $24.90 01/22/2025 Covered Recipient Physician A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, EVENT-DRIVEN STUDY TO INVESTIGATE THE EFFECT OF RETATRUTIDE ON THE INCIDENCE OF MAJOR ADVERSE CARDIOVASCULAR EVENTS AND THE DECLINE IN KIDNEY FUNCTION IN PARTICIPANTS WITH BODY MASS INDEX GREATER THAN 27 KG M2 AND ATHEROSCLEROTIC CARDIOVASCULAR DISEASE AND OR CHRONIC KIDNEY DISEASE No dispute reported 06/30/2026 1187873813
Principal investigator 1 Janssen Research & Development, LLC $279.00 01/21/2025 Non-covered Recipient Entity
N Amercn Rsrch Inst
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 1175167313
Principal investigator 1 CSL Behring $1,362.12 01/16/2025 Non-covered Recipient Entity
North America Research Institute
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252667719
Principal investigator 1 CSL Behring $9,614.90 01/10/2025 Non-covered Recipient Entity
North America Research Institute
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252667629
Principal investigator 1 CSL Behring $21,423.20 01/10/2025 Non-covered Recipient Entity
North America Research Institute
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252667631
Principal investigator 1 AstraZeneca Pharmaceuticals LP $6,998.18 01/08/2025 Non-covered Recipient Entity
NORTH AMERICA RESEARCH INSTITUTE
TA description Cardiovascular Renal and Metabolism Indications Chronic Kidney Disease Study status Ongoing Phase descripton Phase 3 Category R&D Sponsored Delivery model Internal No dispute reported 06/30/2026 1185538144
Principal investigator 1 Novartis Pharmaceuticals Corporation $798,905.65 01/07/2025 Non-covered Recipient Entity
NORTH AMERICA RESEARCH INSTITUTE
A Rollover Extension Program (REP) to Evaluate the Long-term Safety and Tolerability of Open Label Iptacopan/LNP023 in Participants With Primary IgA Nephropathy No dispute reported 06/30/2026 1190302101
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 01/01/2025 Non-covered Recipient Entity
California Kidney Specialists
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220718505
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 01/01/2025 Non-covered Recipient Entity
California Kidney Specialists
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220718507